Indonesia ongoing

Trial name or title	Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine (MTC Belu) Sub-title: Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia: a Randomized Cluster Trial
Methods	Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment Cluster randomized.
Participants	Target sample size: 1488 participants Inclusion criteria: • All villagers of the all selected clusters Exclusion criteria: • Pregnant women during their first trimester • Single dose PQ should not be given for infants under one year-old, pregnant women in all trimesters of pregnancy, breast-feeding mother and patients with G6PD deficiency Age minimum: N/AAge maximum: N/AGender: Both
Interventions	Drug: dihydroartemisinin-piperaquine Drug: PQ (1) intervention arm of mass screening and treatment with interval of 6 weeks; (2) intervention arm of mass screening and treatment with interval of three months; and (3) control arm without mass screening and treatment. The intervention arm with six weeks interval represents a new proposed method to detection malaria infections, while the intervention arm with three month interval represents the Ministry of Health current policy of active case detection in Indonesia, and the third arm will serve as the control for Ministry of Health's policy. No arm without PQ
Outcomes	Malaria incidence (time frame: six months) Anemia (time frame: six months)
Starting date	June 2013
Contact information	Indonesia University/ Walter and Eliza Hall Institute of Medical Research
Notes	http://clinicaltrials.gov/show/NCT01878357 Stated to be completed